Lamb KE, Lodhi S, Meier-Kriesche HU: Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011, 11 (3): 450-462. 10.1111/j.1600-6143.2010.03283.x.
Article
CAS
PubMed
Google Scholar
Reinders ME, Rabelink TJ, de Fijter JW: The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr Opin Organ Transplant. 2013, 18 (1): 44-50. 10.1097/MOT.0b013e32835c2939.
Article
CAS
PubMed
Google Scholar
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8 (4): 315-317. 10.1080/14653240600855905.
Article
CAS
PubMed
Google Scholar
Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L: Immunological characterization of multipotent mesenchymal stromal cells–The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013, 15 (9): 1054-1061. 10.1016/j.jcyt.2013.02.010.
Article
PubMed
Google Scholar
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284 (5411): 143-147. 10.1126/science.284.5411.143.
Article
CAS
PubMed
Google Scholar
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995, 16 (4): 557-564.
CAS
PubMed
Google Scholar
Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005, 105 (4): 1815-1822. 10.1182/blood-2004-04-1559.
Article
CAS
PubMed
Google Scholar
Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003, 101 (9): 3722-3729. 10.1182/blood-2002-07-2104.
Article
CAS
PubMed
Google Scholar
English K, French A, Wood KJ: Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell. 2010, 7 (4): 431-442. 10.1016/j.stem.2010.09.009.
Article
CAS
PubMed
Google Scholar
Franquesa M, Hoogduijn MJ, Baan CC: The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Curr Opin Organ Transplant. 2012, 17 (4): 355-361. 10.1097/MOT.0b013e328355a886.
Article
PubMed
Google Scholar
Tolar J, Le Blanc K, Keating A, Blazar BR: Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010, 28 (8): 1446-1455. 10.1002/stem.459.
Article
PubMed Central
PubMed
Google Scholar
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002, 99 (10): 3838-3843. 10.1182/blood.V99.10.3838.
Article
CAS
PubMed
Google Scholar
Ohnishi S, Sumiyoshi H, Kitamura S, Nagaya N: Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett. 2007, 581 (21): 3961-3966. 10.1016/j.febslet.2007.07.028.
Article
CAS
PubMed
Google Scholar
Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A. 2003, 100 (14): 8407-8411. 10.1073/pnas.1432929100.
Article
PubMed Central
CAS
PubMed
Google Scholar
Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM: Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007, 40 (12): 893-899. 10.1016/j.clinbiochem.2007.04.017.
Article
CAS
PubMed
Google Scholar
Alfarano C, Roubeix C, Chaaya R, Ceccaldi C, Calise D, Mias C, Cussac D, Bascands JL, Parini A: Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant. 2013, 21 (9): 2009-2019. 10.3727/096368912X640448.
Article
Google Scholar
Franquesa M, Herrero E, Torras J, Ripoll E, Flaquer M, Goma M, Lloberas N, Anegon I, Cruzado JM, Grinyo JM, Herrero-Fresneda I: Mesenchymal Stem Cell Therapy Prevents Interstitial Fibrosis and Tubular Atrophy in a Rat Kidney Allograft Model. Stem Cells Dev. 2012, 21 (17): 3125-3135. 10.1089/scd.2012.0096.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, Huss R, Akis N, Schlondorff D, Anders HJ: Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 2006, 70 (1): 121-129. 10.1038/sj.ki.5001521.
Article
CAS
PubMed
Google Scholar
Li L, Zhang Y, Li Y, Yu B, Xu Y, Zhao S, Guan Z: Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. Transpl Int. 2008, 21 (12): 1181-1189. 10.1111/j.1432-2277.2008.00742.x.
Article
CAS
PubMed
Google Scholar
Reinders ME, Leuning DG, de Fijter JW, Hoogduijn MJ, Rabelink TJ: Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders. Curr Pharm Des. 2014, 20 (14): 2412-2429. 10.2174/13816128113199990477.
Article
CAS
PubMed
Google Scholar
Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, Cook HT: Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells. 2006, 24 (11): 2448-2455. 10.1634/stemcells.2006-0201.
Article
CAS
PubMed
Google Scholar
Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T: Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?. Stem Cells. 2013, 31 (10): 2033-2041. 10.1002/stem.1452.
Article
CAS
PubMed
Google Scholar
Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013, 95 (3): 410-417. 10.1097/TP.0b013e31827d62e3.
Article
CAS
PubMed
Google Scholar
Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013, 95 (9): 1113-1119. 10.1097/TP.0b013e3182888db6.
Article
CAS
PubMed
Google Scholar
Loupy A, Hill GS, Jordan SC: The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012, 8 (6): 348-357. 10.1038/nrneph.2012.81.
Article
CAS
PubMed
Google Scholar
Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, Liu JC, Zhang JZ, Wu TJ: Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc. 2006, 38 (9): 3046-3051. 10.1016/j.transproceed.2006.10.002.
Article
CAS
PubMed
Google Scholar
Eggenhofer E, Popp FC, Mendicino M, Silber P, Van’t Hof W, Renner P, Hoogduijn MJ, Pinxteren J, van Rooijen N, Geissler EK, Deans R, Schlitt HJ, Dahlke MH: Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med. 2013, 2 (8): 595-606. 10.5966/sctm.2012-0166.
Article
PubMed Central
CAS
PubMed
Google Scholar
Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S, Rota C, Morigi M, Introna M, Maranta R, Perico N, Remuzzi G, Noris M: Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. Am J Transplant. 2012, 12: 2373-2383. 10.1111/j.1600-6143.2012.04115.x.
Article
CAS
PubMed
Google Scholar
Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H: Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009, 9 (8): 1760-1772. 10.1111/j.1600-6143.2009.02721.x.
Article
CAS
PubMed
Google Scholar
Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasà M, Golay J, Noris M, Remuzzi G: Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011, 6 (2): 412-422. 10.2215/CJN.04950610.
Article
PubMed Central
PubMed
Google Scholar
Perico N, Casiraghi F, Gotti E, Introna M, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Noris M, Remuzzi G: Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int. 2013, 26 (9): 867-878. 10.1111/tri.12132.
Article
CAS
PubMed
Google Scholar
Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C: Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012, 307 (11): 1169-1177. 10.1001/jama.2012.316.
Article
CAS
PubMed
Google Scholar
Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP: Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013, 95 (1): 161-168. 10.1097/TP.0b013e3182754c53.
Article
CAS
PubMed
Google Scholar
Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, Claas FH, van Miert PP, Roelen DL, van Kooten C, Fibbe WE, Rabelink TJ: Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study. Stem Cells Transl Med. 2013, 2 (2): 107-111. 10.5966/sctm.2012-0114.
Article
PubMed Central
CAS
PubMed
Google Scholar
Reinders ME, Roemeling-van Rhijn M, Khairoun M, Lievers E, de Vries DK, Schaapherder AF, Wong SW, Zwaginga JJ, Duijs JM, van Zonneveld AJ, Hoogduijn MJ, Fibbe WE, de Fijter JW, van Kooten C, Rabelink TJ, Roelofs H: Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy. 2013, 15 (6): 663-672. 10.1016/j.jcyt.2013.01.010.
Article
CAS
PubMed
Google Scholar
Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, Hutchinson JA, Vogt K, Schlickeiser S, Kverneland AH, Meisel C, Volk HD, Sawitzki B: Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res. 2013, 2 (1): 17-10.1186/2047-1440-2-17.
Article
PubMed Central
PubMed
Google Scholar
Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW, Colvin RB, Sykes M, Sachs DH: HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008, 358 (4): 353-361. 10.1056/NEJMoa071074.
Article
PubMed Central
CAS
PubMed
Google Scholar
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med. 2003, 349 (24): 2326-2333. 10.1056/NEJMoa020009.
Article
CAS
PubMed
Google Scholar
Seron D, Moreso F: Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int. 2007, 72 (6): 690-697. 10.1038/sj.ki.5002396.
Article
CAS
PubMed
Google Scholar
Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roos-van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, ten Berge I, Florquin S: No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006, 17 (1): 305-312. 10.1681/ASN.2005030249.
Article
CAS
PubMed
Google Scholar
Scholten EM, Rowshani AT, Cremers S, Bemelman FJ, Eikmans M, van Kan E, Mallat MJ, Florquin S, Surachno J, ten Berge IJ, Bajema IM, de Fijter JW: Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol. 2006, 17 (9): 2622-2632. 10.1681/ASN.2006030227.
Article
PubMed
Google Scholar
Grimm PC, Nickerson P, Gough J, McKenna R, Jeffery J, Birk P, Rush DN: Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant. 1999, 3 (4): 257-270. 10.1034/j.1399-3046.1999.00044.x.
Article
CAS
PubMed
Google Scholar
Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN: Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol. 2003, 14 (6): 1662-1668. 10.1097/01.ASN.0000066143.02832.5E.
Article
PubMed
Google Scholar
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007, 357 (25): 2562-2575. 10.1056/NEJMoa067411.
Article
CAS
PubMed
Google Scholar
Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009, 4 (2): 481-508.
CAS
PubMed
Google Scholar
Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001, 71 (9): 1282-1287. 10.1097/00007890-200105150-00017.
Article
CAS
PubMed
Google Scholar
Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007, 7 (3): 560-570. 10.1111/j.1600-6143.2006.01645.x.
Article
CAS
PubMed
Google Scholar
Holdaas H, Rostaing L, Seron D, Cole E, Chapman J, Fellstrom B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators: Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation. 2011, 92 (4): 410-418. 10.1097/TP.0b013e318224c12d.
Article
CAS
PubMed
Google Scholar
Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009, 87 (2): 233-242. 10.1097/TP.0b013e3181927a41.
Article
CAS
PubMed
Google Scholar
Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F: Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2012, 377 (9768): 837-847. 10.1016/S0140-6736(10)62318-5.
Article
Google Scholar
Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wuthrich RP, Scheidl S, May C, Paulus EM, Mühlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O, ZEUS Study Investigators: Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant. 2011, 12 (6): 1528-1540. 10.1111/j.1600-6143.2012.03994.x.
Article
Google Scholar
Group CSC: Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014, 26: ᅟ-ahead of print
Google Scholar
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004, 78 (4): 557-565. 10.1097/01.TP.0000128636.70499.6E.
Article
CAS
PubMed
Google Scholar
Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O’Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation. 2001, 71 (4): 515-523. 10.1097/00007890-200102270-00006.
Article
CAS
PubMed
Google Scholar
Nankivell BJ, Kuypers DR, Fenton-Lee CA, Allen RD, O’Connell PJ, Chapman JR: Histological injury and renal transplant outcome: the cumulative damage hypothesis. Transplant Proc. 2001, 33 (1–2): 1149-1150. 10.1016/S0041-1345(00)02806-2.
Article
CAS
PubMed
Google Scholar
de Fijter JW: Rejection and function and chronic allograft dysfunction. Kidney Int Suppl. 2010, 119: S38-41. 10.1038/ki.2010.421.
Article
CAS
PubMed
Google Scholar
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004, 78 (2): 242-249. 10.1097/01.TP.0000128167.60172.CC.
Article
PubMed
Google Scholar
Schwarz A, Mengel M, Gwinner W, Radermacher J, Hiss M, Kreipe H, Haller H: Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int. 2005, 67 (1): 341-348. 10.1111/j.1523-1755.2005.00087.x.
Article
PubMed
Google Scholar
Diaz Encarnacion MM, Griffin MD, Slezak JM, Bergstralh EJ, Stegall MD, Velosa JA, Grande JP: Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant. 2004, 4 (2): 248-256. 10.1046/j.1600-6143.2003.00311.x.
Article
PubMed
Google Scholar
Roos-van Groningen MC, Scholten EM, Lelieveld PM, Rowshani AT, Baelde HJ, Bajema IM, Florquin S, Bemelman FJ, de Heer E, de Fijter JW, Bruijn JA, Eikmans M: Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol. 2006, 17 (3): 881-888. 10.1681/ASN.2005080891.
Article
CAS
PubMed
Google Scholar
Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, Smith RN, Grimm PC, Colvin RB: Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol. 2011, 22 (1): 176-186. 10.1681/ASN.2009091005.
Article
PubMed Central
PubMed
Google Scholar
Casiraghi F, Remuzzi G, Abbate M, Perico N: Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. Stem Cell Rev. 2012, 9 (1): 65-79. 10.1007/s12015-011-9345-4.
Article
Google Scholar
Salem HK, Thiemermann C: Mesenchymal stromal cells: current understanding and clinical status. Stem Cells. 2010, 28 (3): 585-596.
PubMed Central
CAS
PubMed
Google Scholar
Moermans C, Lechanteur C, Baudoux E, Giet O, Henket M, Seidel L, Lejeune M, Willems E, Baron F, Beguin Y: Impact of Cotransplantation of Mesenchymal Stem Cells on Lung Function After Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Following Non-Myeloablative Conditioning. Transplantation. 2014, 98 (3): 348-353. 10.1097/TP.0000000000000068.
Article
PubMed
Google Scholar
Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998, 9 (12 Suppl): S16-23.
CAS
PubMed
Google Scholar
Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation. 2001, 72 (6 Suppl): S5-8. 10.1097/00007890-200109271-00003.
Article
CAS
PubMed
Google Scholar
Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000, 11 (9): 1735-1743.
CAS
PubMed
Google Scholar
Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RW, Kandaswamy R, Dunn DL, Najarian JS, Sutherland DE: Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int. 2002, 62 (2): 704-714. 10.1046/j.1523-1755.2002.00491.x.
Article
PubMed
Google Scholar
Morales JM, Marcen R, Andres A, Molina MG, Castillo DD, Cabello M, Capdevila L, Campistol JM, Oppenheimer F, Seron D, Vernet SG, Lampreave I, Valdés F, Anaya F, Escuín F, Arias M, Pallardó L, Bustamante J: Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney Int Suppl. 2008, 111: S94-99. 10.1038/ki.2008.547.
Article
PubMed
Google Scholar
Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators: Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail. 2013, 1 (5): 389-399. 10.1016/j.jchf.2013.07.002.
Article
PubMed
Google Scholar
Hester J, Schiopu A, Nadig SN, Wood KJ: Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant. 2012, 12 (8): 2008-2016. 10.1111/j.1600-6143.2012.04065.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larse CP, Ahmed R: mTor regulates memory CD8 T-cell differentiation. Nature. 2009, 460 (7251): 108-112. 10.1038/nature08155.
Article
PubMed Central
CAS
PubMed
Google Scholar